Thalidomide-O-PEG4-Propargyl manufacturers
|
| | Thalidomide-O-PEG4-Propargyl Basic information |
| Product Name: | Thalidomide-O-PEG4-Propargyl | | Synonyms: | Thalidomide-O-PEG4-Propargyl;4-((3,6,9,12-tetraoxapentadec-14-yn-1-yl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;Thalidomide-PEG4-Propargyl;E3 Ligase Ligand-Linker Conjugates,Thalidomide-PEG-4-Propargyl,inhibit,Inhibitor,Thalidomide PEG4 Propargyl,ThalidomidePEG4Propargyl;1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)-;Thalidomide-4-PEG4-O-Propargyl;2-(2,6-Dioxo-3-piperidinyl)-4-(3,6,9,12-tetraoxapentadec-14-yn-1-yloxy)-1H-isoindole-1,3(2H)-dione | | CAS: | 2098799-77-8 | | MF: | C24H28N2O9 | | MW: | 488.49 | | EINECS: | | | Product Categories: | peg;PROTACs-Please select | | Mol File: | 2098799-77-8.mol |  |
| | Thalidomide-O-PEG4-Propargyl Chemical Properties |
| Boiling point | 673.9±55.0 °C(Predicted) | | density | 1.320±0.06 g/cm3(Predicted) | | storage temp. | -20°C, stored under nitrogen | | solubility | Soluble in Water, DMF, DCM, DMSO | | pka | 10.70±0.40(Predicted) | | form | Solid | | color | White to light yellow |
| | Thalidomide-O-PEG4-Propargyl Usage And Synthesis |
| Description | Thalidomide-O-PEG4-Propargyl is synthesized compound that incorporates the Thalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology, Propargyl is reactive with azide molecule in the presence of Cu catalyst. | | Uses | Thalidomide-PEG4-Propargyl is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. Thalidomide-PEG4-Propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | | IC 50 | Cereblon | | References | [1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326 [2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-998. DOI:10.1016/j.str.2020.07.015 |
| | Thalidomide-O-PEG4-Propargyl Preparation Products And Raw materials |
|